Coreline Soft is expanding its presence in the European medical AI market through a partnership with Germany-based Raya Diagnostics, as lung cancer screening enters a new phase of institutional adoption across the region.
The company announced on March 31 that it will collaborate with Raya Diagnostics to broaden access to AI-powered lung cancer screening across the DACH region, which includes Germany, Austria, and Switzerland. The partnership will integrate Coreline Soft’s AI solutions into Raya’s radiology platform, RayaONE, embedding them directly into existing RIS/PACS workflows and enabling wider deployment across radiology networks.
The move comes as Germany’s Federal Joint Committee (G-BA) recently approved national health insurance coverage for low-dose CT lung cancer screening, a decision expected to accelerate demand while raising the need for standardized operations and quality control.
As lung cancer screening becomes institutionalized across Europe, the role of AI is evolving beyond image analysis toward supporting end-to-end screening operations. Given the long-term nature of lung cancer screening, which requires follow-up exams and ongoing patient management, operational elements such as nodule tracking, follow-up interval decisions, discrepancy resolution, and reporting standardization are becoming increasingly critical.
In response, AI tools are expanding their capabilities to include triage, structured reporting, automated tracking metrics, and quality assurance (QA) support. This shift reflects a broader transition toward what industry observers describe as “operational AI.”
Large hospitals, including leading institutions such as Charité in Germany, are playing a key role in establishing standardized protocols that are subsequently adopted by regional imaging centers. With reimbursement now in place, Germany is seeing increased screening volumes alongside stricter requirements for follow-up management and quality standards, further driving demand for integrated AI solutions.
Through this partnership, Coreline Soft and Raya aim to extend standardized, guideline-aligned screening environments beyond large hospitals to smaller imaging centers. By embedding AI outputs directly into existing clinical workflows rather than using separate systems, the companies seek to improve usability and accelerate network-wide adoption.
Across Europe, a combination of radiology workforce shortages and rising screening demand is intensifying the need for scalable, high-quality screening systems. Smaller centers, in particular, face greater gaps in specialized expertise, making access to standardized tools a key competitive factor.
At the same time, policy developments such as the expansion of the UK’s NHS screening programs, Germany’s reimbursement rollout, and France’s integration into public healthcare infrastructure are reshaping the European lung cancer screening landscape. Competitive dynamics are shifting away from standalone AI accuracy toward alignment with national screening systems, multi-center operability, quality management, and data standardization capabilities.
Coreline Soft is strengthening its infrastructure through its AVIEW HUB platform, which supports multi-center reading, quality control, and data anonymization. Industry analysts suggest that such operational capabilities could become a significant barrier to entry in the evolving European medical AI market.
